Netrin-4 delays colorectal cancer carcinomatosis by inhibiting tumor angiogenesis

American Journal of Pathology

Volumn 178, Issue 4, 2011, Pages 1861-1869

  Eveno, Clarisse ^a   Broqueres You, Dong ^a,b   Feron, Jean Guillaume ^a,b   Rampanou, Aurore ^a   Tijeras Raballand, Annemilaï ^a,b   Ropert, Stanislas ^a,b   Leconte, Laurence ^a,b   Levy, Bernard I ^a,b   Pocard, Marc ^a  

^a Université René Diderot   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; COMPLEMENTARY DNA; MATRIGEL; NEOGENIN; NETRIN; NETRIN 4; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG PROTEIN BINDING; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

EID: 79953660723     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.12.019     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96
2. Lieberman D: Progress and challenges in colorectal cancer screening and surveillance. Gastroenterology 2010, 138:2115-2126
3. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vernon SW, Cronin K, Edwards BK: The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000, 88:2398-2424
4. Dvorak HF: Angiogenesis: update 2005. J Thromb Haemost 2005, 3:1835-1842
5. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 2005, 438:967-974 (Pubitemid 43093963)
6. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186
7. Zhong H, Bowen JP: Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr Med Chem 2006, 13:849-862
8. Ivy SP, Wick JY, Kaufman BM: An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009, 6:569-579
9. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380
10. Karkkainen MJ, Petrova TV: Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000, 19:5598-5605
11. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 2002, 196:1497-1506 (Pubitemid 35424943)
12. Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron 1992, 9:383-391
13. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203-212
14. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-1136 (Pubitemid 351398487)
15. Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergun S, Schadendorf D: Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010, 207:491-503
16. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT: Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010, 70:1063-1071
17. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML, Wu L: Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010, 115:1461-1471
18. Freitas C, Larrivee B, Eichmann A: Netrins and UNC5 receptors in angiogenesis. Angiogenesis 2008, 11:23-29
19. Pasquale EB: Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010, 10:165-180
20. Cirulli V, Yebra M: Netrins: beyond the brain. Nat Rev Mol Cell Biol 2007, 8:296-306 (Pubitemid 46474658)
21. Dumartin L, Quemener C, Laklai H, Herbert J, Bicknell R, Bousquet C, Pyronnet S, Castronovo V, Schilling MK, Bikfalvi A, Hagedorn M: Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology 2010, 138:1595-1606.
22. Lejmi E, Leconte L, Pedron-Mazoyer S, Ropert S, Raoul W, Lavalette S, Bouras I, Feron JG, Maitre-Boube M, Assayag F, Feumi C, Alemany M, Jie TX, Merkulova T, Poupon MF, Ruchoux MM, Tobelem G, Sennlaub F, Plouet J: Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B. Proc Natl Acad Sci U S A 2008, 105:12491-12496
23. Nacht M, St Martin TB, Byrne A, Klinger KW, Teicher BA, Madden SL, Jiang Y: Netrin-4 regulates angiogenic responses and tumor cell growth. Exp Cell Res 2009, 315:784-794
24. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992, 67:519-528
25. Harmon RL, Sugarbaker PH: Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2005, 2:3
26. Otto J, Jansen PL, Lucas S, Schumpelick V, Jansen M: Reduction of peritoneal carcinomatosis by intraperitoneal administration of phospholipids in rats. BMC Cancer 2007, 7:104
27. Miles AA, Miles EM: Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. J Physiol 1952, 118:228-257
28. Eichmann A, Makinen T, Alitalo K: Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes Dev 2005, 19:1013-1021 (Pubitemid 40632446)
29. Larrivee B, Freitas C, Trombe M, Lv X, Delafarge B, Yuan L, Bouvree K, Breant C, Del TR, Brechot N, Germain S, Bono F, Dol F, Claes F, Fischer C, Autiero M, Thomas JL, Carmeliet P, Tessier-Lavigne M, Eichmann A: Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes Dev 2007, 21:2433-2447 (Pubitemid 47533561)
30. Lu X, Le NF, Yuan L, Jiang Q, De Lafarge B, Sugiyama D, Breant C, Claes F, De SF, Thomas JL, Autiero M, Carmeliet P, Tessier-Lavigne M, Eichmann A: The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature 2004, 432:179-186 (Pubitemid 39545842)
31. Wilson BD, Ii M, Park KW, Suli A, Sorensen LK, Larrieu-Lahargue F, Urness LD, Suh W, Asai J, Kock GA, Thorne T, Silver M, Thomas KR, Chien CB, Losordo DW, Li DY: Netrins promote developmental and therapeutic angiogenesis. Science 2006, 313:640-644 (Pubitemid 44201136)
32. Numnum TM, Rocconi RP, Whitworth J, Barnes MN: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006, 102:425-428 (Pubitemid 44353660)
33. Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006, 107:83-89 (Pubitemid 43939034)
34. Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G, Sizemore N: The AKT/I κ B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-κ B and β-catenin. Oncogene 2005, 24:1021-1031